来自官方财务报表的收入、利润与现金流历史。
Alkermes plc 是一家生物制药公司，致力于药品的研究、开发和商业化，以满足美国、爱尔兰和国际治疗领域患者未满足的医疗需求。该公司拥有一系列用于治疗阿片类药物依赖、酒精依赖、精神分裂症、I型双相情感障碍的专有商业产品，以及一系列正在开发的神经系统疾病临床和临床前候选产品。其上市产品包括ARISADA，一种用于治疗精神分裂症的肌内注射混悬液； Aristada INITIO 用于治疗成人精神分裂症； VIVITROL 用于治疗酒精和预防阿片类药物依赖； LYBALVI，一种口服非典型抗精神病候选药物，用于治疗成人精神分裂症和 I 型双相情感障碍； LUMRYZ 是一种缓释口服混悬液产品，用于治疗儿科患者的猝倒或 EDS。该公司还向第三方提供专有技术平台，使他们能够开发、商业化和制造产品。它主要与 Janssen Pharmaceutica N.V.、Janssen Pharmaceutica Inc 和 Janssen Pharmaceutica International 签订了合作协议。 Alkermes plc 成立于 1987 年，总部位于爱尔兰都柏林。
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $1.7B | $1.5B | $1.6B | $1.7B | $1.1B | $1.2B | $1.0B | $1.2B | $1.1B | $903M | $746M | $628M | $619M | $596M | $576M | $576M | $390M | $187M | $178M | $327M | $241M |
| 毛利 | $1.4B | $1.3B | $1.3B | $1.4B | $894M | $976M | $860M | $991M | $918M | $749M | $614M | $489M | $443M | — | $265M | $405M | $262M | $134M | $129M | $283M | $200M |
| 毛利率% | 84.6% | 86.7% | 84.2% | 84.8% | 80.4% | 83.2% | 82.8% | 84.6% | 83.9% | 82.9% | 82.3% | 77.9% | 71.6% | 69.0% | 46.1% | 70.4% | 67.3% | 72.0% | 72.3% | 86.7% | 83.1% |
| 营业利润（EBIT） | $117M | $254M | $421M | $414M | ($6M) | $98M | ($112M) | ($175M) | ($99M) | ($148M) | ($209M) | ($224M) | ($87M) | $16M | $82M | $82M | ($88M) | ($46M) | ($43M) | $135M | ($3M) |
| 营业利润率% | 7.0% | 17.2% | 27.0% | 24.9% | -0.5% | 8.3% | -10.8% | -15.0% | -9.1% | -16.4% | -28.0% | -35.7% | -14.1% | 3.6% | 14.2% | 14.2% | -22.6% | -24.4% | -24.1% | 41.3% | -1.2% |
| 净利 | $66M | $242M | $367M | $356M | ($158M) | ($48M) | ($111M) | ($197M) | ($139M) | ($158M) | ($208M) | ($227M) | ($30M) | $18M | $25M | $25M | ($114M) | ($46M) | ($40M) | $131M | $167M |
| 净利润率 % | 4.0% | 16.4% | 23.6% | 21.4% | -14.2% | -4.1% | -10.7% | -16.8% | -12.7% | -17.5% | -28.0% | -36.1% | -4.9% | 4.1% | 4.3% | 4.3% | -29.1% | -24.4% | -22.2% | 39.9% | 69.4% |
| EBITDA | $218M | $331M | $495M | $519M | $60M | $178M | ($6M) | ($103M) | ($8M) | ($33M) | ($105M) | ($125M) | $97M | $66M | $115M | $158M | ($38M) | ($35M) | ($14M) | $155M | $16M |
| 每股收益（EPS） | $0.39 | $1.43 | $2.17 | $2.10 | $-0.97 | $-0.30 | $-0.70 | $-1.25 | $-0.90 | $-1.03 | $-1.38 | $-1.52 | $-0.21 | $0.12 | $0.18 | $0.18 | $-1.19 | $-0.48 | $-0.42 | $1.36 | $1.62 |
| 已发行股数 (M) | 167M | 169M | 169M | 170M | 164M | 161M | 159M | 157M | 155M | 153M | 151M | 149M | 145M | 145M | 137M | 137M | 96M | 96M | 95M | 96M | 103M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 ALKS 交互式查看器。 /companies/us/ALKS
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms